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Non-biased investigation of standardized Ginkgo biloba preparations 
by  1H NMR-Based Metabolomics and HPLC-PDA-MS-SPE-NMR
Sara Agnolet1, Jerzy W. Jaroszewski1, Robert Verpoorte2, and Dan Stærk1,3
BACKGROUND
Extracts of Ginkgo biloba leaves are among the best selling herbal preparations worldwide and are used for improvement of the peripheral and 
central blood circulation, improvement of memory, symptomatic treatment of dementia, Alzheimer’s disease as well as for their antioxidant and 
neuro-protective activities.
Commercial preparations are very complex mixtures prepared from raw leaf extract by a series of extraction and prepurification steps. During this 
process the extracts are enriched in some compounds while other compounds are removed. 
The final Ginkgo biloba extract (EGb 761) are standardized to contain 24% flavonoids and 6% terpene trilactones (TTL’s; 3.1% ginkgolides and 
2.9% bilobalide) which are considered the active constituents. However the current quality control does not assure the same distribution of 
individual TTL’s and flavonoid glycosides from batch-to-batch or brand-to-brand and other constituents that may possess pharmacological activity 
are not included in the standardization.
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RESULTS AND DISCUSSION
SAMPLE PREPARATION
NMR ANALYSIS DATA PREPROCESSING DATASET FOR PCA ANALYSIS
METHODOLOGY
Samples of all tablets and capsules were prepared in triplicate by extraction of pulverized material with 70% methanol. The dry residue was dissolved in acetone-d6, and 1H NMR spectra of all extracts were acquired at a 
resonance frequency of 600 MHz. All 1H-NMR spectra were reduced to 850 sequencially integrated spectral regions (buckets) of 0.01 ppm width from 0.5 to 9 ppm using Bruker AMIX software. PCA analysis were performed 
using SIMCA-P software on centered data.   
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In the current work, 1H NMR-based metabolomics was used for non-biased investigation of the global composition of 16 commercially-available Ginkgo biloba preparations. In addition, hyphenation of HPLC, PDA, MS, 
and NMR with an automated solid-phase extraction (SPE) device, i.e., HPLC-PDA-MS-SPE-NMR, was used for identification of eight major flavonoid glycosides.
HPLC ANALYSIS
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1: R1 = OH R2 = H
2: R1 = H R2 = Rha(2 1)Glc(6 1)Coumaroyl ester
3: R1 = OH R2 = Rha(2 1)Glc(6 1)Coumaroyl ester
4: R1 = H R2 = Rha(2 1)Glc
5: R1 = OCH3 R2 = Glc(6 1)Rha
6: R1 = H R2 = Glc(6 1)Rha
7: R1 = OH R2 = Rha(2 1)Glc
8: R1 = OH R2 = Glc(6 1)Rha
HPLC-PDA-MS-SPE-NMR was used for the  isolation of 8 selected flavonoids. Peaks 
were trapped 8 times on a SPE cartridges using threshold-based absorbance at 254 
nm for selection of analytes. 
Lack of commercially available reference substances for flavonol glycosides is a well 
know problem in the analysis of flavonoids.
HPLC-PDA-MS-SPE-NMR has constituted a fast and reliable method for the 
identification of the major flavonoids in Ginkgo biloba extracts.
CONCLUSIONS
1H-NMR based metabolomics is able to discriminate between the various preparations according to their global composition. The analysis disclosed differences in the content of flavonol glycosides and terpene 
trilactones, as well differences in other constituents normally not considered in the standardization procedure. 1H-NMR based metabolomics constitute an attractive method for global characterization of 
standardized Ginkgo biloba preparations. 
PCA analysis was performed on 
the entire spectrum. The 
preparations results separated 
based on their relative content of  
shikimic acid and ginkgolides. 
Discrimination between relative 
content of single TTL’s was 
possible. Sample 4 and 10 cluster 
together for the presence of citric 
acid as excipient.
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Citric acid constitute a frequently used excipient in pharmaceutical preparations. However, as 
demonstrated in a recent publication (Larsen et al., 2009), citric acid can form potentially harmful reaction 
products with constituents of pharmaceutical preparations and its addition in complex extract like Ginkgo 
biloba extracts should therefore preferably be avoided. 
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A separated model was performed in the aromatic region of the spectra and 
further characterization of the samples based on the relative amount of TTLs
and flavonoids was possible. 
The same dataset but scaled on the total intensity, enabled the 
identification of ginkgolic acid in sample 8 and observation of 
quercetin as almost the only flavonoid in sample 9, clear 
symptom of fortification.
A measure of the relative amount of the single TTLs (normalized to sum of 
6%) can be easily obtained from the buckets and results equivalent to the 
manual integration of the peaks. The relative amount of TTL’s confirm the 
results of PCA analysis.
ACTIVE CONSTITUENTS OF GINKGO BILOBA
STRUCTURE IDENTIFICATION
